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Abstract
With the ameliorated resectability prowess of endoscopic techniques, a myriad of diseases previously treated by major
ablative surgeries are now endoscopically curable. Endoscopic submucosal tunnel dissection (ESTD) is a relatively new
technique that has diversified endoscopic application. Although ESTD has frequently been used for the resection of esophageal
neoplastic lesions, the clinical evidence pertaining to its efficacy in the treatment of circumferential Barrett’s esophagus
remains sparse. In this study, we evaluated ESTD as a potential therapeutic technique in patients with Barrett’s esophagusrelated high-grade dysplasia. The tunneling strategy helped achieve complete en bloc resection at an increased dissection
speed, without any procedural complications. This article illustrates that ESTD can be a feasible, safe, and effective treatment
for dysplastic Barrett’s esophagus. Future research should aim to stratify the potential risks and complications associated
with this optimization of endoscopic submucosal dissection in patients with superficial esophageal lesions.
Keywords
endoscopic submucosal tunnel dissection, Barrett’s esophagus, high-grade dysplasia, circumferential esophageal lesions,
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Introduction
Barrett’s esophagus has been estimated to affect up to 1%
to 2% of the adult population in Western countries.1,2 It is
disconcerting that 7% to 19% of patients with high-grade
dysplasia in Barrett’s esophagus may progress to esophageal adenocarcinoma.3,4 Endoscopic therapy is preferred in
these patients as it circumvents the morbidity and mortality
associated with surgical intervention.5 Due to curative
resection and lower recurrence rates, endoscopic submucosal dissection (ESD) has gained precedence over endoscopic mucosal resection (EMR) for dysplastic lesions and
early esophageal neoplasms.6 Conversely, the widespread
use of conventional ESD for the management of Barrett’s
esophagus has frequently been hindered due to its relatively
long procedure times, technical complexity, steep learning
curve, and potential risk for serious adverse events.6 While
treating esophageal lesions, endoscopists may also face difficulty in scope manipulation owing to the thinness of the
muscularis propria and the narrow luminal diameter of the
esophagus. These factors increase the risk of perforation,
rendering the uptake of conventional esophageal ESD a
challenge. Therefore, optimization of ESD is warranted to
mitigate these disadvantages, especially in patients with
circumferential esophageal lesions.

Endoscopic submucosal tunnel dissection (ESTD) is a
relatively new technique that affords faster dissection when
compared with conventional ESD.7 The effectiveness of tunneling strategy has been demonstrated in the treatment of a
multitude of gastrointestinal lesions.8 However, published
medical literature pertaining to its therapeutic applications for
high-grade dysplasia secondary to circumferential Barrett’s
esophagus remains limited. In this study, we attempted tunneling technique in patients with Barrett’s dysplasia, resulting
in curative resection. Given the technical feasibility and better
clinical outcomes, we propose that ESTD can be an alternative endoscopic treatment for circumferential Barrett’s esophagus. We hope this article serves to enable clinicians the
ability to stratify procedural risks and complications of this
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Figure 1. Endoscopic appearance of the esophagus
demonstrating nodular mucosa, extending from 23 to 35 cm from
incisors. The Paris classification type was 0-IIa+IIc, indicating
superficial elevated lesions (black arrow) as well as areas with
central depressions (blue arrow).

technique to select candidates in future and spare such patients
from esophagectomy.

Patients and Methods
Case 1
An 85-year-old male with a history of hypertension and
benign prostatic hyperplasia underwent evaluation of his
previously diagnosed Barrett’s esophagus. His prior endoscopies showed salmon-colored nodular mucosa, with a
Paris classification phenotype of 0-IIa+IIc, located at 23 to
35 cm from the incisors (Figure 1). Biopsy confirmed multifocal high-grade dysplasia, with no evidence of carcinoma
(Figure 2). The patient was considered a suitable candidate
for surgical intervention but he refused the procedure due to
the associated risks. As it was a 12-cm long, high-grade,
nodular dysplastic Barrett’s lesion, radiofrequency ablation
could not form the initial optimal treatment. Due to his
favorable geriatric performance status, a multidisciplinary
team with expertise in surgery and advanced endoscopy
recommended ESTD. The patient was educated about this
treatment modality. Informed consent was obtained after
discussing benefits and risk of potential complications such
as perforation, bleeding, and stenosis associated with circumferential submucosal dissection. Ethical approval was
duly obtained for the modification of the conventional ESD
procedure.
A forward-viewing endoscope (GIF-H180; Olympus) with
a transparent cap (MH-588; Olympus) was advanced to the
lesion. The proximal and distal margins of Barrett’s esophagus were marked with DualKnife (Olympus). Submucosal
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Figure 2. Histopathologic examination of the biopsy specimen
from nodular esophagus showing Barrett’s mucosa with
high-grade dysplasia (arrows), but no evidence of malignancy
(hematoxylin and eosin staining; 400×).

solution was injected and a 2-cm horizontal mucosal incision
was made in the posterior wall. With the use of repeat submucosal injection and DualKnife, a posterior submucosal tunnel
was created, extending up to the gastroesophageal junction.
Similarly, an anterior submucosal tunnel was created. After
partially extending the anterior tunnel to the posterior tunnel
on the left side, a circumferential mucosal incision was made
near to the gastroesophageal junction using DualKnife, which
removed the distal mucosal portion. The anterior tunnel was
then extended posteriorly on the right side, creating a 360°
tunnel. The proximal mucosal incision was extended circumferentially using a combination of Dual and HookKnife electrocauteries (Olympus). Proximal residual Barrett’s mucosa
was then dissected. It resulted in the en bloc removal of the
12-cm long, circumferential dysplastic esophageal lesion
(Figure 3).
During and after the completion of ESTD, only one actively
oozing visible blood vessel was identified. The coagulation
was successfully performed with coagulating forceps
(Coagrasper, FD-410L; Olympus). A fully covered metallic
esophageal stent (Boston Scientific) was placed across the
ESTD base and was secured by endosuturing (Supplementary
File; Video 1, available online). Postprocedural barium swallow showed no evidence of a filling defect (Figure 4).
Pathologic analysis of the resected specimen confirmed dysplastic Barrett’s mucosa, with no neoplastic changes (Figure 5).
The horizontal and vertical margins of the resected specimen
were free of Barrett’s mucosa.

Case 2
An 81-year-old male presented to our hospital for the evaluation of Barrett’s esophagus (Prague C3M4), noted at 41 to
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Figure 3. Gross morphology of the esophageal lesion after en
bloc circumferential removal using endoscopic submucosal tunnel
dissection.

Figure 5. The histopathologic analysis of the resected specimen
confirmed the presence of dysplastic Barrett’s mucosa (arrows)
and there was no evidence of malignancy (hematoxylin and eosin
staining; 400×).

Figure 4. Postprocedural barium swallow showing no visible
evidence of a leak.

Figure 6. Upper endoscopy showing Barrett’s esophagus
(Prague C3M4), located at 41 to 44 cm from the incisors
(blue arrows). A dysplastic mass lesion noted at 42 cm from
the incisors (black arrows), the morphology of the lesion was
consistent with the Paris classification type, protruding sessile (Is).

44 cm from the incisors. Upper endoscopy showed a mass
lesion, morphologically consistent with the Paris classification type of protruding sessile (Is), noted at 42 to 44 cm from
the incisors (Figure 6). The gastroesophageal junction mass
was located at 4 to 5 o’clock position (Figure 7). On endoscopic ultrasonography, the lesion was mucosal-based, with
no regional lymphadenopathy. Biopsy results confirmed
high-grade dysplasia in Barrett’s esophagus. The patient was
mobile with good geriatric performance status but refused
surgical intervention. Given the nodularity and high-grade
dysplasia in Barrett’s esophagus, radiofrequency ablation
was not considered the optimal first treatment. Based on a
multidisciplinary input, it was decided to treat the lesion

using ESTD. This therapeutic option was explained to the
patient. Informed consent was obtained after discussing the
risks, benefits, and limitations of ESTD. Ethical approval
was also obtained prior to the procedure.
A forward-viewing endoscope (GIF-H180; Olympus)
was used to inject submucosal solution into the posterior
wall and a linear horizontal mucosal incision was made at
40 cm. Posterior submucosal tunnel was created using
DualKnife (Olympus) and was extended into cardia up to 45
cm. Submucosal solution was then injected into the anterior
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Figure 7. Endoscopic features of the gastroesophageal junction
dysplastic mass located at around 4 to 5 o’clock position
(arrows).

wall. A linear, horizontal, mucosal incision was made; anterior submucosal tunnel was created and extended into cardia. A near-circumferential mucosal incision was made in
cardia at 45 cm using a DualKnife in a retroflexed position.
Submucosal solution was then injected starting in the right
and left positions. After making a linear horizontal mucosal
incision, complete submucosal tunnel was created, and
extended into cardia. The lesion was now hanging near cardia. After repeat submucosal injection, the lesion was
removed with a combination of HookKnife and snare cautery (Olympus). During the last part of dissection, the lesion
broke into 2 large and 2 smaller pieces. All pieces were
retrieved and placed on gel foam. The resected specimens
were sent for histopathologic examination.
A pair of coagulating forceps (Coagrasper, FD-410L;
Olympus) was used to coagulate residual vessels at the ESTD
base. In order to prevent restenosis, 80 mg of triamcinolone
was injected at different spots in the ESTD base. As a precautionary measure against delayed bleeding, 5 mL of human
plasma-derived fibrin sealant (EVICEL) was also sprayed at
the ESTD base. The en bloc removal of the mass lesion along
with the Barrett’s mucosa from 40 to 45 cm from the incisors
was completed without any potential complications.
Pathologic examination of the resected specimens confirmed
negative horizontal and vertical mucosal resection margins
for Barrett’s esophagus.

Outcomes and Follow-up
In Case 1, the total procedural time was 105 minutes. The
patient was discharged from the hospital in a stable condition after 2 days of endoscopic curative resection. He recuperated rapidly in the aftermath of the ESTD treatment,
with prompt improvement in his clinical condition. At the
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1-week follow-up, he had no complaints and was tolerating
solid food. The esophageal stent was removed after 2
months. At the 6-month follow-up, the patient developed a
post-ESTD mild, short distal esophageal stricture that was
easily managed by balloon dilation. Endoscopic examination, at the 12-month follow-up visit ruled out recurrence.
At the subsequent endoscopic follow-ups as per the postresection surveillance guidelines of the American Society of
Gastrointestinal Endoscopy for Barrett’s esophagus-related
high-grade dysplasia, no complications or recurrence was
evident. The patient continues to do well to date, totaling 5
years and 3 months.
In Case 2, the whole procedure took 60 minutes, with no
immediate periprocedural complications. His length of hospital stay was also short, comprizing of 2 days. The subsequent endoscopic follow-ups at 3, 6, 9, 12, and 18 months
ruled out recurrence, stricture, or any other delayed procedural complications, with a total follow-up duration of 1 year
and 11 months. He continues to be symptom-free, with no
evidence of recurrence of the disease thus far. In both cases,
no residual dysplasia or intestinal metaplasia was noted on
surveillance endoscopic biopsies.

Discussion
Linghu et al first coined the term endoscopic submucosal
tunnel dissection in 2013 after they published their research
regarding the use of tunnel technique for large circular early
esophageal cancer.9 At present, the application range of this
technique covers a variety of gastrointestinal disorders. The
lesions, such as superficial esophageal squamous cell carcinoma, esophageal leiomyoma, large esophageal mucosal
lesions, submucosal esophageal and gastric precancerous
lesions, ulcerative early gastric cancer, lesser gastric curvature superficial neoplasms, intramural esophageal bronchogenic cysts, giant colorectal subpedunculated neoplastic
lesions, colorectal lateral spreading tumors, and large superficial rectal neoplasms, are shown to be amenable to ESTD.10-12
Recently, a few studies also reported the use of a concoction
of the tunnel technique and the clip-with-line traction
method to perform esophageal ESD for the treatment of
superficial esophageal neoplasms.13,14 However, in patients
with circumferential Barrett’s-associated high-grade dysplasia, the application of tunneling technique remains limited.
The present study further adds to the existing clinical evidence and highlights the efficacy of ESTD in the treatment
of Barrett’s esophagus.
In comparison to conventional ESD, ESTD has a higher
dissection speed, yields fewer adverse events, and has better
curative rates. The backbone of this technique is the creation
of a submucosal tunnel to secure a working space. It provides
a “good view” for dissection that ultimately helps in the lateral stretching of the mucosa. Air insufflation is of relative
ease and the effect of submucosal injection is prolonged.10
Major benefits of tunnel creation include the prevention of
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mucosal collapse due to the intratunnel pressure and easier
identification of proper submucosal cutting planes.15
Imperatively, the tunneling greatly decreases the time
required for wound healing. Furthermore, the risks of perforation and gastrointestinal infection are significantly
decreased.10 ESTD is also associated with a relatively shorter
hospital stay and low recurrence rates, making it more feasible.5 In this study, the total hospital stay in Cases 1 and 2
was 2 days, respectively.
The risk of peri- or postprocedural hemorrhage ranges
from 0% to 5.9% in ESTD.10 However, the provision of a
better visual field makes primary hemostasis easier to
achieve in ESTD than conventional ESD.16 If bleeding
occurs in the submucosal tunnel, it can be controlled by
pressing the bleeding point by tip of the endoscope. After
preparing for hemostasis, the pressing is released and coagulation of the bleeding point can be performed by hemostatic forceps.17 Therefore, a vast majority of patients with
minor bleeding can be effectively managed using the aforementioned method in the submucosal tunnel. Even though
major bleeding events are extremely rare, identification of
the culprit vessel with water jet followed by blind coagulation with hemostatic forceps might be warranted in some
patients. Endoscopic hemoclip placement may also be used
to curb bleeding from large residual vessels if conservative
treatment fails to secure hemostasis.17 Although reactionary
hemorrhage rarely occurs after ESTD, it can usually be
managed endoscopically.17
Perforation remains an important potential complication
of ESTD, with an estimated risk of up to 4%.10,18 When it
occurs, the perforation usually measures <10 mm and can
easily be controlled with metal clipping. Multiple clips in a
zipper fashion are preferred to achieve complete closure. A
recent over-the-scope clip (OTSC) technique may secure
up to a 20-mm perforation with adequate compression
impact.18 The larger defects are managed with fully covered
self-expandable metal stents, but their migration may pose
a challenge.19 Surgery can be indicated if endoscopic closure fails, patients develop severe mediastinal infection,
and/or in the setting of hemodynamic compromise. In this
study, the total procedural blood loss in Cases 1 and 2 was
<5 mL, respectively. Delayed bleeding and perforation
were effectively ruled out by the post-procedure endoscopy
and barium-swallow.
Postprocedure stenosis or stricture formation can be a particularly debilitating complication. In a study of 84 esophageal ESD patients, the stenosis rate of ≥3/4 circular lesions
was 90%.20 Therefore, the prevention of this adverse event
after circumferential ESTD should be considered exceedingly imperative. Chai et al10 suggested a fully covered metal
stent placement for a period of 4 to 8 weeks. Furthermore,
hormone injection or oral administration, balloon dilatation,
endoscopic radical incision, auto balloon dilatation, and
autoplastic flap transplantation are among other commonly
used methods in clinical practice.20-22 However, no standard

5
therapy is available to prevent postoperative stricture after
ESTD. In this study, we deployed an esophageal stent in
Case 1, whereas a steroid injection was administered in Case
2. The patients showed excellent clinical recovery with resolution of their prior symptoms. At the subsequent follow-ups,
the first patient showed a mild stricture formation after stent
removal, which was successfully treated with endoscopic
balloon dilatation. The second patient had no signs of gastrointestinal blood loss or stricture formation at long-term
follow-up.
With regard to post-resection surveillance in patients with
dysplastic Barrett’s esophagus, current guidelines of the
American Society of Gastrointestinal Endoscopy are largely
based on expert opinion and low-quality clinical evidence.23
Initial endoscopic evaluation at 3 to 6 months after achieving
complete eradication of intestinal metaplasia (CE-IM) is recommended followed by surveillance intervals on the basis of
pretreatment histopathologic features. In patients with baseline detection of high-grade dysplasia, surveillance endoscopic examination every 3 months in the first year after
CE-IM followed by endoscopies every 6 months in 2 years
followed by yearly endoscopies has been suggested. In cases
with low-grade dysplasia who have achieved CE-IM, the
most recent guidelines suggest surveillance every year for 2
years and then every 3 years.24 The guidelines favor the histologic confirmation of recurrent intestinal metaplastic or
neoplastic changes by surveillance biopsy sampling after
achieving CE-IM.25,26 The patients involved in this study
underwent endoscopic post-ESTD surveillance in accordance with the aforementioned guidelines. At the follow-up
visits, no clinical or endoscopic evidence of recurrence was
noted in these patients. Surveillance endoscopic biopsies
ruled out residual dysplasia or intestinal metaplasia in both
the cases. Thus, ESTD emerged as a safe and efficacious
modality for the excision of dysplastic epithelium in Barrett’s
esophagus.

Learning Points
•• ESTD can be considered a part of the armamentarium
for the management of Barrett’s esophagus.
•• It allows the en bloc resection of the large and circumferential dysplastic Barrett’s mucosa, with relatively
shorter dissection time and decreased incidence of
intraoperative complications than conventional ESD.
•• Given the low risk of recurrence and fewer adverse
events, this organ-sparing technique may-be beneficial over other endoscopic treatments and surgical
resection, especially in patients with Barrett’s-related
high-grade dysplasia.
•• This case series prompts endoscopists to conduct further studies on the long-term efficacy of ESTD. The
comparison of this technique with other interventional
therapies for Barrett’s esophagus is also warranted.
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